AZD8421

Other Medications

Description

AZD8421 is an experimental drug currently being studied by AstraZeneca. It is being investigated in clinical trials for various advanced solid tumors, including colorectal cancer. The trials are in the early phase (Phase 1), primarily focused on determining the safety and tolerability of the drug, both when given alone and in combination with other cancer treatments. The goal of these early trials is to find the right dose and understand how the drug works in the body before moving to larger studies to test its effectiveness. The specific role of AZD8421 in colorectal cancer treatment is still under investigation.

Mechanism of Action

AZD8421 is a new drug, and its exact mechanism of action (how it works in the body to fight cancer) is still being studied. Clinical trials are evaluating its effects on cancer cells and how it interacts with other drugs. It is being tested alone and in combination with other targeted therapies.

Side Effects

As AZD8421 is an investigational drug in early-phase clinical trials The full range of potential side effects is still being evaluated. The primary focus of the current trials is to assess the safety and tolerability of the drug. Information about specific side effects will become clearer as the trials progress. Participants in these trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06188520 Phase 1
Recruiting
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
United States, Australia, South Korea, Spain, United Kingdom